<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">Secondary malignancies</z:e> due to <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> or <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> are a concern in patients treated for primary brain <z:hpo ids='HP_0004375'>tumors of the nervous system</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">Myelosuppression</z:e> is the dose-limiting toxic effect of the <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> temozolomide; reversible hematologic toxicity consisting mainly of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> is reported to occur in 7% of patients treated with concomitant radiotherapy and temozolomide and 14% with adjuvant temozlomide.(1) However, the incidence of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> and nonreversible <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e>, such as <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), are a rare complication of temozolomide.(2.) </plain></SENT>
</text></document>